References
1. Fox KA, Birkhead J, Wilcox R, et al. British Cardiac Society Working Group on the definition of myocardial infarction. Heart 2004;90:603–609.
2. Abdella NA, Mojiminiyi OA, Akanji AO, et al. Associations of plasma homocysteine concentration in subjects with type 2 diabetes mellitus. Acta Diabetol 2002;39:183–190.
3. Booth GL, Wang EE. Preventive health care, 2000 update: screening and management of hyperhomocystinemia for the prevention of coronary artery disease events: the Canadian Task Force on Preventive Health Care. CMAJ 2000;163:21–29.
4. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Nat Acad Sci U S A 1993;90:1004–1008.
5. Bertina RM, Koeleman BP, Koster T, et al. Mutation in the blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–67.
6. Cumming AM, Shiach CR. The investigation and management of inherited thrombophilia. Clin Lab Haematol 1999;21:77–92.
7. Marangon K, O’Byrne D, Devaraj S, et al. Validation of an immunoassay for measurement of plasma total homocysteine. Am J Clin Pathol 1999;112:757–762.
8. Collection, Transport and Preparation of Blood Specimens for Coagulation Testing and Performance of Coagulation Assays. NCCLS Document H21-A2 1991; Vol 11, No. 23.
9. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230–236.
10. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group.Ann Intern Med 1999;130:461–470.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
12. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997;277:1775–1781.
13. Hacker SM, Williamson BD, Lisco S, et al. Protein C deficiency and acute myocardial infarction in the third decade. Am J Cardiol 1991;68:137–138.
14. Kario K, Matsuo T, Tai S, et al. Congenital protein C deficiency and myocardial infarction: concomitant factor VII hyperactivity may play a role in the onset of arterial thrombosis. Thromb Res1992;67:95–103.
15. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990;75:895–901.
16. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost1999;25:333–350.
17. Lowe GD, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the Third Glasgow MONICA Survey: I, illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775–784.
18. Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3–32.
19. Galli M, Luciani D, Bertolini G, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.Blood 2003;101:1827–1832.
20. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995;91:23–27.
21. Tuhrim S, Rand JH, Wu XX, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999;30:1561–1565.
22. Sutton-Tyrrell K, Bostom A, Selhub J, et al. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation 1997;96:1745–1749.
23. Welch GN, Loscalzo J. Homocysteine and atherosclerosis. N Engl J Med 1998;338:1042–1050.
24. Lesniak W, Kolasinska-Kloch W, Kiec B. Vascular endothelium: function, disorders and clinical modification probes. Folia Med Cracov 2001;42:5–14.
25. Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst (e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997;96:2542–2544.
26. Hayashi T, Honda G, Suzuki K. An atherogenic stimulus homocysteine inhibits cofactor activity of thrombomodulin and enhances thrombomodulin expression in human umbilical vein endothelial cells.Blood 1992;79:2930–2936.
27. Ridker PM, Hennekens CH, Selhub J, et al. Interrelation of hyperhomocyst (e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997;95:1777–1782.
28. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocystinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997;11:1157–1168.
29. Khare A, Ghosh K, Shetty S, et al. Combination of thrombophilia markers in acute myocardial infarction of the young. Indian J Med Sci 2004;58:381–388.
30. Kark JD, Sinnreich R, Rosenberg IH, et al. Plasma homocysteine and parental myocardial infarction in young adults in Jerusalem. Circulation 2002;105:2725–2729.
31. Selhub J, Jacques PF, Wilson PWF, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–2697.
32. Joosten E, van den Berg A, Riezler R, et al. Metabolic evidence that deficiencies of vitamin B-12 (cobalamin), folate, and vitamin B-6 occur commonly in elderly people. Am J Clin Nutr 1993;58:468–476.
33. Graham I, Meleady R. Heart attacks and homocysteine. BMJ 1996;313:1419–1420.